



Real World Outcomes of patients treated for wet Age related Macular Degeneration: a study from Pune, India.

Dr. Sucheta Kulkarni, Dr. Varun Doshi, Dr. Rashmi Kashikar, Dr. Sagar Aghadate
PBMA's H. V. Desai Eye Care Institute, Pune, India.

Aim:

To study the profile of patients treated for wet age related macular degeneration (AMD) at a tertiary eye care institute in western India and to report real world outcomes at one year after treatment with anti-VEGF injections.

Methods:

- Historic cohort study (Jan 2022-Dec 2023)
- Retrospective chart review to identify treatment naïve wet AMD who received anti-VEGF.
- Ocular co-morbidities and incomplete data excluded.
- Data collected: Demographics, Baseline and one year visual acuity, type and number of injections received, OCT characteristics at baseline and at one year, mode of payment
- Visual and anatomical outcomes at one year.
- Statistical association between mode of payment and number of injections.

Results:

- Total eyes treated: 220, LTFU- 113 (51.4%)
- Included in study: 107 eyes (48.6%) of 81 pts
- Mean number of inj: 4.2 (SD 2.1, 95% CI 3.8- 4.6.)

Table 1: Characteristics of study population

Mean age	68.2 years (range 53-89, SD 5.6)
Sex	Males 58.6%
Mode of payment	
OOP	27 (33.3%)
Insurance	54 (66.6%)
Mean number of injections	
OOP	2.8, SD 1.5, 95% CI 2.2- 3.3;
Insurance	4.4, SD 1.9, 95% CI 3.9- 4.9, (p< 0.001)

Results:

Table 2: Types of injections used

Name	N (%)
Bevacizumab	45 (42)
Ranibizumab	9 (8.5)
Aflibercept	3 (2.8)
Brolucizumab	12 (11.2)
Multiple types	38 (35.5)
TOTAL	107 (100)

Table 3: Change in vision and OCT features from Baseline to one year.

Vision and OCT features	Baseline N (%)	Year 1 follow up N (%)	
BCVA (LogMAR)	0.94 (SD 0.6, 95% CI 0.82- 1.05)	0.77 (SD 0.38, 95% CI 0.65- 0.84)	p- 0.01
Intraretinal fluid	48 (45)	27 (25.4)	p- 0.005
Subretinal fluid	23 (21.5)	3 (3)	p- 0.007
Pigment epithelial detachment	3 (2.8)	8 (7.4)	p- 0.53
Mixed features	33 (30.8)	10 (9)	p- 0.002
No activity	0 (0)	59 (55.2)	P< 0.001
TOTAL	107 (100)	107 (100)	

Conclusions:

- Stable vision despite suboptimal treatments in real world scenario.
- Financing mechanisms for frequent treatments may improve treatment adherence.

Learnings:

Poor compliance remains the biggest challenge and sustained awareness efforts, and financing mechanisms are needed for better outcomes.